
For millions of Indians living with progressive, inherited blindness, a single eye injection could soon rewrite the future of ophthalmic care. Developed by US-based biotechnology firm Nanoscope Therapeutics, MOGENRY (scientifically known as sonpiretigene isteparvovec or MCO-010) has captured global medical attention after the U.S. Food and Drug Administration accepted its Biologics License Application and Japan’s regulatory agency granted it priority review in late 2026. Co-founded by Indian-origin scientist Dr. Samarendra Mohanty—an alumnus of IIT Delhi and IISc Bangalore—the therapy offers a radical departure from conventional gene treatments by bypassing damaged eye cells altogether. For India, where inherited retinal diseases affect roughly one in every 1,000 people compared to one in 4,000 globally, this gene-agnostic breakthrough could eliminate the biggest barriers to sight-saving care: complex genetic testing, invasive retinal surgery, and prohibitively narrow eligibility criteria.
What Is MOGENRY Therapy and How Does It Restore Sight?
MOGENRY is a one-time, in-office intravitreal optogenetic gene therapy engineered to treat severe vision loss caused by retinitis pigmentosa (RP), a group of rare inherited disorders that progressively destroy light-sensing cells in the eye. In a healthy human eye, specialized photoreceptor cells—known as rods and cones—capture incoming light and convert it into electrical signals that travel through deeper layers of retinal neurons to the brain. When retinitis pigmentosa strikes, genetic mutations steadily wipe out these rods and cones, leaving patients with night blindness, tunnel vision, and eventually legal or total blindness. However, even after photoreceptors die off, the underlying layers of retinal cells, particularly dense networks of bipolar cells, remain intact and connected to the optic nerve. Instead of attempting to repair the dead rods and cones, MOGENRY uses a harmless viral vector to deliver a proprietary synthetic gene called Multi-Characteristic Opsin (MCO) directly into those surviving bipolar cells. Once inside, the MCO protein transforms the bipolar cells into brand-new light sensors that respond to ordinary ambient light without requiring bulky external goggles, headsets, or surgical retinal implants.
Why a Gene-Agnostic Approach Changes Everything
Traditional gene therapies operate like precision sniper rifles: they target and fix one broken gene at a time. For instance, Luxturna, the first FDA-approved retinal gene therapy, only works for patients carrying mutations in both copies of a single gene called RPE65—a group that accounts for roughly two percent of recessive retinitis pigmentosa cases. Because inherited retinal dystrophies are linked to more than 1,000 distinct mutations across over 250 different genes, single-gene therapies leave the overwhelming majority of patients without any viable medical option. MOGENRY takes a completely different route by acting as a gene-agnostic therapy. Because it activates downstream bipolar cells rather than correcting the original faulty DNA, it works regardless of which specific genetic mutation caused the patient’s blindness. In clinical trials such as the Phase 2b/3 RESTORE study, adults with advanced retinitis pigmentosa whose vision had deteriorated past 20/1600—essentially limited to perceiving hand motion or light—experienced statistically significant improvements in visual acuity after receiving a single dose, with gains sustained at 52 and 76 weeks.
How Much Benefit Will Indian Patients Actually Get?
The potential impact of MOGENRY on India’s healthcare landscape is immense, largely due to the country’s unique demographic and diagnostic realities. Epidemiological estimates indicate that retinitis pigmentosa is nearly four times more prevalent in India than the global average, driven in part by higher rates of consanguineous marriages in certain regions, translating to well over a million Indians grappling with progressive inherited vision loss. Today, Indian patients diagnosed with RP face a bleak clinical reality limited to vitamin A supplementation, cataract management, UV-protective lenses, and low-vision magnifiers. Moreover, advanced next-generation genetic sequencing panels in metro hubs like New Delhi, Mumbai, Bengaluru, Hyderabad, and Chennai remain expensive and out of reach for families in tier-2 and tier-3 districts. Because MOGENRY removes the strict prerequisite of identifying an exact mutated gene before treatment and is delivered as a routine outpatient eye injection rather than a complex vitreoretinal surgery, tertiary eye institutes across India could deploy it far more easily than existing gene therapies. Beyond retinitis pigmentosa, Nanoscope is also advancing MCO-based therapies for Stargardt disease, Leber congenital amaurosis, and geographic atrophy linked to age-related macular degeneration, broadening the long-term horizon for millions of older Indian adults.
Current Availability, Cost Hurdles, and the Road Ahead
Despite the excitement surrounding its scientific ingenuity, patients and families in India must temper their expectations with practical timelines. As of November 2026, MOGENRY remains an investigational therapy and is not yet commercially approved or available anywhere in the world. Regulatory reviews are actively underway with the US FDA and Japan’s Pharmaceuticals and Medical Devices Agency, while separate clinical pathways and regulatory approvals from India’s Central Drugs Standard Control Organisation (CDSCO) will be required before Indian hospitals can administer the injection. Affordability will also be the defining battleground for Indian healthcare policymakers. Global gene therapies routinely carry price tags exceeding several crores of rupees per eye, putting them far beyond the reach of out-of-pocket Indian patients unless subsidized through domestic manufacturing partnerships, government rare-disease funds, or tiered pricing models. Additionally, clinical data shows that while over half of high-dose trial participants achieved meaningful visual gains by week 76, individual responses vary, and the therapy is designed to restore functional vision rather than 20/20 eyesight. Until Indian regulatory trials open, retina specialists advise patients across India to maintain regular check-ups, protect their eyes from UV glare, and use low-vision aids to preserve their remaining visual pathways for the day treatments like MOGENRY finally arrive.
North India Statesman